Drug Discovery World

SEPTEMBER 26, 2022

According to MarketWatch, the drug repurposing sector was thought to be worth $25,280 in 2021 and is expected to grow to $30,620 million by 2028 with a CAGR of 2.8%. Indeed, having a safety profile already established could entice patients to enter clinical trials more readily than with ‘unknown’ compounds. . Benefits and barriers .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

Agency IQ

AUGUST 16, 2024

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. FDA accepted the Lykos NDA in February 2024, and the submission received priority review.

FDA 40

FDA Trials Regulations Therapies 40

Drug Discovery World

AUGUST 10, 2022

And now, with more than 600 CAR T trials recruiting or ongoing, these cells represent a majority of the cellular immunotherapies in development today. For example, it is challenging to regulate transgene copy numbers in each T cell, posing safety risks. Measuring the pharmacokinetics of CAR T cells.

Therapies 246

Therapies Virus Treatment Engineering 246